JPM

Anupam Rama

Q: How accurate are Anupam Rama's stock ratings?

About 52% of Anupam's ratings were profitable over a one-year hold, with an average return of +4.3% per rating, measured by 13Foresight from historical prices.

Q: How is Anupam ranked?

Anupam Rama is ranked #1276 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

J.P. Morgan

Wall Street Analyst

★★★☆☆

#1276

on 13Foresight · ranked by our own returns

52%

Success Rate

+4.3%

Average Return

40 of 77 calls profitable · +40.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 52% of Anupam Rama's ratings turned a profit when each position was held for 1 year — averaging +4.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

170 Buy 24 Hold 6 Sell

Anupam's Stock Coverage 53 ratings · 2026-08-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
RARE Ultragenyx Pharmaceutical	Aug 19, 2026	BUY	Strong Buy +153.6% avg upside 36 analysts	—	·	·
TRAX First Tracks Biotherapeutics Inc	Aug 19, 2026	BUY	Strong Buy +39.9% avg upside 8 analysts	$65.00 45.41% Upside	·	·
VERA Vera Therapeutics	Aug 17, 2026	BUY	Strong Buy +113.5% avg upside 19 analysts	$76.00 141.79% Upside	·	·
OLMA Olema Pharmaceuticals	Aug 17, 2026	BUY	Strong Buy +245.3% avg upside 16 analysts	$46.00 318.17% Upside	-1.1%	·
CTMX CytomX Therapeutics	Aug 17, 2026	BUY	Strong Buy +203.9% avg upside 21 analysts	$11.00 213.78% Upside	·	·
PROK ProKidney	Aug 13, 2026	HOLD	Buy +350.6% avg upside 12 analysts	—	-5.3%	·
BBIO BridgeBio Pharma	Aug 12, 2026	BUY	Strong Buy +13.0% avg upside 34 analysts	$111.00 33.13% Upside	-6.0%	·
SLDB Solid Biosciences	Aug 11, 2026	BUY	Strong Buy +64.9% avg upside 23 analysts	$11.00 16.78% Upside	+1.5%	·
SNDX Syndax Pharmaceuticals	Aug 11, 2026	BUY	Strong Buy +70.7% avg upside 27 analysts	$40.00 96.64% Upside	+0.1%	·
IDYA IDEAYA Biosciences	Aug 10, 2026	BUY	Strong Buy +25.5% avg upside 29 analysts	$62.00 63.11% Upside	-0.5%	·
REPL Replimune Group	Aug 10, 2026	BUY	Strong Buy +55.6% avg upside 14 analysts	$20.00 39.58% Upside	+9.5%	·
TVTX Travere Therapeutics	Aug 06, 2026	BUY	Strong Buy -12.3% avg upside 22 analysts	$90.00 39.03% Upside	+1.7%	·
ORIC Oric Pharmaceuticals	Aug 06, 2026	BUY	Strong Buy +64.2% avg upside 19 analysts	$23.00 60.95% Upside	+13.3%	·
NBIX Neurocrine	Aug 06, 2026	BUY	Strong Buy +20.6% avg upside 37 analysts	$217.00 40.35% Upside	-4.4%	·
KOD Kodiak Sciences	Aug 03, 2026	BUY	Strong Buy +31.5% avg upside 11 analysts	$66.00 67.78% Upside	+3.8%	·
KNSA Kiniksa Pharmaceuticals	Jul 29, 2026	BUY	Strong Buy -4.1% avg upside 11 analysts	$107.00 34.97% Upside	-5.1%	·
KARD Kardigan, Inc.	Jul 13, 2026	BUY	Strong Buy +97.6% avg upside 4 analysts	$51.00 132.82% Upside	-14.1%	·
CAMP CAMP4 Therapeutics Corporation	Jun 22, 2026	BUY	Strong Buy +111.6% avg upside 9 analysts	$9.00 97.83% Upside	+29.5%	·
FULC Fulcrum Therapeutics	Jun 02, 2026	SELL	Hold +138.2% avg upside 14 analysts	—	-19.1%	·
COGT Cogent Biosciences	May 31, 2026	BUY	Strong Buy +1.8% avg upside 26 analysts	—	+7.4%	·
ANAB AnaptysBio	May 22, 2026	BUY	Strong Buy +22.3% avg upside 26 analysts	$70.00 18.71% Upside	-2.1%	·
MAZE Maze Therapeutics, Inc.	May 22, 2026	BUY	Strong Buy +113.7% avg upside 12 analysts	$53.00 79.50% Upside	+13.0%	·
ZLAB Zai Lab	May 22, 2026	BUY	Strong Buy +123.0% avg upside 13 analysts	$27.00 2.96% Upside	+37.4%	·
SRPT Sarepta Therapeutics	May 18, 2026	HOLD	Buy +208.6% avg upside 49 analysts	$19.00 1.78% Downside	+6.4%	·
ERAS Erasca	May 13, 2026	BUY	Strong Buy +15.1% avg upside 14 analysts	$23.00 32.26% Upside	+72.8%	·
BMEA Biomea Fusion	Mar 24, 2026	SELL	Strong Buy +859.1% avg upside 15 analysts	—	-16.8%	·
ANNX Annexon Biosciences	Mar 18, 2026	BUY	Strong Buy +157.7% avg upside 14 analysts	—	-2.4%	·
AGMB AgomAb Therapeutics NV ADR	Mar 03, 2026	BUY	Strong Buy +120.8% avg upside 6 analysts	$32.00 132.71% Upside	-16.9%	·
ENTA Enanta Pharmaceuticals	Mar 03, 2026	BUY	Buy +143.6% avg upside 17 analysts	$19.00 40.92% Upside	-10.6%	·
VOR Vor Biopharma	Dec 18, 2025	BUY	Buy +88.4% avg upside 17 analysts	$40.00 75.27% Upside	+79.9%	·
NVAX Novavax	Nov 18, 2025	SELL	Buy +180.5% avg upside 20 analysts	$6.00 28.43% Downside	-19.8%	·
RLYB Rallybio	May 14, 2024	HOLD	Buy +37.6% avg upside 8 analysts	—	-83.2%	·
ALNY Alnylam Pharma	Feb 01, 2024	HOLD	Strong Buy +34.8% avg upside 51 analysts	$170.00 29.03% Downside	+55.1%	·
KLRS Kalaris Therapeutics	Dec 22, 2023	SELL	Strong Buy +207.8% avg upside 13 analysts	—	+47.2%	·
ATRA Atara Biotherapeutics	Aug 15, 2022	HOLD	Buy +90.2% avg upside 18 analysts	$5.00 46.26% Downside	-65.5%	·
BCAB BioAtla	May 11, 2022	BUY	Strong Buy +2837.1% avg upside 13 analysts	$26.00 702.49% Upside	·	·
CYTK Cytokinetics	May 11, 2022	BUY	Strong Buy +17.3% avg upside 36 analysts	$64.00 16.10% Downside	+2.5%	·
SYRE Spyre Therapeutics	May 10, 2022	BUY	Strong Buy -11.2% avg upside 23 analysts	$8.00 92.54% Downside	-88.8%	·
AGIO Agios Pharma	May 10, 2022	HOLD	Strong Buy +77.0% avg upside 29 analysts	$48.00 40.68% Upside	+18.4%	·
PTGX Protagonist Therapeutics	May 06, 2022	BUY	Strong Buy -22.5% avg upside 19 analysts	$45.00 70.32% Downside	+172.6%	·
PASG Passage Bio	Mar 08, 2022	HOLD	Buy +288.5% avg upside 14 analysts	—	-50.7%	·
TBPH Theravance Biopharma	Feb 25, 2022	HOLD	Hold +8.6% avg upside 18 analysts	$13.00 23.46% Downside	-3.6%	·
SRRK Scholar Rock Holding	Nov 12, 2021	BUY	Strong Buy +2.7% avg upside 23 analysts	$55.00 0.77% Downside	-75.8%	·
VIR Vir Biotechnology	Oct 25, 2021	HOLD	Strong Buy +165.1% avg upside 16 analysts	$37.00 290.64% Upside	-46.9%	·
INFIQ Infinity Pharmaceuticals	Aug 05, 2021	BUY	Buy +647142757.2% avg upside 8 analysts	$6.00 599999899.93% Upside	·	·
KRRO Korro Bio	Mar 25, 2021	SELL	Strong Buy +95.8% avg upside 19 analysts	$10.00 26.73% Downside	·	·
DYN Dyne Therapeutics	Oct 12, 2020	BUY	Strong Buy +49.8% avg upside 31 analysts	$27.00 4.10% Upside	-22.1%	·
IFRX InflaRx	Jun 05, 2019	SELL	Buy +318.9% avg upside 11 analysts	—	-144.8%	·
RIGL Rigel	Mar 01, 2019	BUY	Strong Buy -41.7% avg upside 17 analysts	$6.00 86.95% Downside	-5.4%	·
PTCT PTC Therapeutics	Nov 16, 2017	HOLD	Buy +10.3% avg upside 29 analysts	—	+113.6%	·
PTC PTC	Sep 29, 2017	HOLD	Buy -4.5% avg upside 31 analysts	—	+88.7%	·
IRWD Ironwood Pharma	Jul 21, 2017	HOLD	Hold +173.0% avg upside 23 analysts	$19.00 348.19% Upside	+16.3%	·
MESO Mesoblast	Jun 15, 2016	HOLD	Strong Buy +44.6% avg upside 14 analysts	—	+84.4%	·

🔒 48 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Anupam Rama — Frequently Asked Questions

How accurate are Anupam Rama's stock ratings?

Based on the calls 13Foresight could measure, about 52% of Anupam's ratings were profitable over a one-year hold, with an average return of +4.3% per rating, or +40.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Anupam ranked on 13Foresight?

Anupam Rama is currently ranked #1276 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Anupam cover?

Anupam most recently has ratings on RARE, TRAX, VERA, OLMA, CTMX, PROK, BBIO, SLDB, SNDX, IDYA, REPL, TVTX and 41 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Anupam Rama

Rating Distribution

Welcome to 13Foresight!